PharmaShots | Incisive News in 3 Shots

Subscribe Now

Acumen Pharmaceuticals

Acumen Pharmaceuticals Reports First Patient Dosing with Sabirnetug in P-II (ALTITUDE-AD) Study for Early Alzheimer’s Disease

Acumen Pharmaceuticals Reports First Patient Dosing with Sabirnetug in P-II (ALTITUDE-AD) Study for Early Alzheimer’s Disease

May 9, 2024

PharmaShots Weekly Snapshots (July 17 – 21, 2023)

PharmaShots Weekly Snapshots (July 17 – 21, 2023)

July 22, 2023

Acumen Pharmaceuticals Presents P-I Trial (INTERCEPT-AD) Results of ACU193 for Early Alzheimer’s Disease at AAIC 2023

Acumen Pharmaceuticals Presents P-I Trial (INTERCEPT-AD) Results of ACU193 for Early Alzheimer’s Disease at AAIC 2023

July 17, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us